Cited by 340Barrier Structure and Function StudiesDrug Transport and Resistance MechanismsAlzheimer's disease research and treatments

The DOI matches its Crossref record; 117 of the 117 references it cites were found in a registry or an index.

Blood–Brain Barrier Pathology in Alzheimer's and Parkinson's Disease: Implications for Drug Therapy

Open access

Desai, Brinda S., Monahan, Angela J., Carvey, Paul M., Hendey, Bill·2007·Cell Transplantation

DOI 10.3727/000000007783464731

Open this paper in CoChat — free account

Abstract

The blood–brain barrier (BBB) is a tightly regulated barrier in the central nervous system. Though the BBB is thought to be intact during neurodegenerative diseases such as Alzheimer's (AD) and Parkinson's disease (PD), recent evidence argues otherwise. Dysfunction of the BBB may be involved in disease progression, eliciting of peripheral immune response, and, most importantly, altered drug efficacy. In this review, we will give a brief overview of the BBB, its components, and their functions. We will critically evaluate the current literature in AD and PD BBB pathology resulting from insult, neuroinflammation, and neurodegeneration. Specifically, we will discuss alterations in tight junction, transport and endothelial cell surface proteins, and vascular density changes, all of which result in altered permeability. Finally, we will discuss the implications of BBB dysfunction in current and future therapeutics. Developing a better appreciation of BBB dysfunction in AD and PD may not only provide novel strategies in treatment, but will prove an interesting milestone in understanding neurodegenerative disease etiology and progression.

Integrity signals

Registry

Crossref · 10.3727/000000007783464731

Cites

117 of 117 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Alzheimer’s disease
Blennow, K., de Leon, M. J., & Zetterberg, H. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69113-7 · Cited by 3,134
Reactive microglia are positive for HLA‐DR in the substantia nigra of Parkinson's and Alzheimer's disease brains
McGeer, P. L., Itagaki, S., Boyes, B. E., & McGeer, E. G. (1988) · Neurology · doi:10.1212/wnl.38.8.1285 · Cited by 2,990
J. Submicrosc. Cytol. Pathol.
Thomas, A. C., & Campbell, J. H. (2000) · Cited by 2,800
Stages in the development of Parkinson’s disease-related pathology
Braak, H., Ghebremedhin, E., Rüb, U., Bratzke, H., & Del Tredici, K. (2004) · Cell and Tissue Research · doi:10.1007/s00441-004-0956-9 · Cited by 2,689
Functional polymorphisms of the human multidrug-resistance gene: Multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo
Hoffmeyer, S., Burk, O., von Richter, O., Arnold, H., Brockmöller, J., Johne, A., Cascorbi, I., Gerloff, T., Roots, I., Eichelbaum, M. F., et al. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.7.3473 · Cited by 2,366
Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs
Schinkel, A. H., Smit, J., van Tellingen, O., Beijnen, J. H., Wagenaar, E., van Deemter, L., Mol, C. A. A. M., van der Valk, M. A., Robanus-Maandag, E. C., Riele, H. T., et al. (1994) · Cell · doi:10.1016/0092-8674(94)90212-7 · Cited by 2,284
Size-selective loosening of the blood-brain barrier in claudin-5–deficient mice
Nitta, T., Hata, M., Gotoh, S., Seo, Y., Sasaki, H., Hashimoto, N., Furuse, M., & Tsukita, S. (2003) · The Journal of Cell Biology · doi:10.1083/jcb.200302070 · Cited by 1,917
Treatment with a Copper-Zinc Chelator Markedly and Rapidly Inhibits β-Amyloid Accumulation in Alzheimer's Disease Transgenic Mice
Cherny, R. A., Atwood, C. S., Xilinas, M. E., Gray, D. N., Jones, W. D., McLean, C. A., Barnham, K. J., Volitakis, I., Fraser, F. W., Kim, Y.-S., et al. (2001) · Neuron · doi:10.1016/s0896-6273(01)00317-8 · Cited by 1,447
Clearance of Alzheimer’s amyloid-β1-40 peptide from brain by LDL receptor–related protein-1 at the blood-brain barrier
Shibata, M., Yamada, S., Kumar, S. R., Calero, M., Bading, J., Frangione, B., Holtzman, D. M., Miller, C. A., Strickland, D. K., Ghiso, J., et al. (2000) · Journal of Clinical Investigation · doi:10.1172/jci10498 · Cited by 1,413
The inflammatory response system of brain: implications for therapy of Alzheimer and other neurodegenerative diseases
MCGEER, P., & MCGEER, E. (1995) · Brain Research Reviews · doi:10.1016/0165-0173(95)00011-9 · Cited by 1,287

Show all 117 references

Research works printed but not linked: 14

Bernheimer H., 1973, Clinical, morphological and neurochemical correlations. J. Neurol. Sci., 20, 415
Dahlstrom A., 1990, J. Neural Transm. Suppl., 29, 195
Desai B. S., 2006, Soc. Neurosci. Abstr.
Ehrlich P., 1904, Gesammelte Arbeiten zur Immunitaetsforschung, 574
Goldmann E., 1913, Abhandl Konigl preuss Akad Wiss, 1, 1
Iwasaki T., 1999, J. Med. Dent. Sci., 46, 31
Kalaria R. N., 1992, Cerebrovasc. Brain Metab. Rev., 4, 226
Kemper E. M., 2004, Rev., 30, 415
Larsen N., 2005, Soc. Neurosci. Abstr.
Parachikova A., 2006, Neurobiol. Aging
Sayre L. M., 2000, Cell. Mol. Biol. (Noisy-le-grand), 46, 731
Simpson I. A., 2002, Diabetes Nutr. Metab., 15, 281
Verbeek M. M., 1994, Am. J. Pathol., 144, 104
Zipser B. D., 2006, Neurobiol. Aging;

Sorted by citations

Structure and function of the blood–brain barrier
Abbott, N. J., Patabendige, A. A. K., Dolman, D. E. M., Yusof, S. R., & Begley, D. J. (2010) · Neurobiology of Disease · doi:10.1016/j.nbd.2009.07.030 · Cited by 5,185
A blood–brain barrier overview on structure, function, impairment, and biomarkers of integrity
Kadry, H., Noorani, B., & Cucullo, L. (2020) · Fluids and Barriers of the CNS · doi:10.1186/s12987-020-00230-3 · Cited by 1,853
Modern methods for delivery of drugs across the blood–brain barrier
Chen, Y., & Liu, L. (2011) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2011.11.010 · Cited by 1,038
The Blood-Brain Barrier in Brain Homeostasis and Neurological Diseases
Weiss, N., Miller, F., Cazaubon, S., & Couraud, P.-O. (2009) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2008.10.022 · Cited by 731
Overcoming the Blood–Brain Barrier: The Role of Nanomaterials in Treating Neurological Diseases
Furtado, D., Björnmalm, M., Ayton, S., Bush, A. I., Kempe, K., & Caruso, F. (2018) · Advanced Materials · doi:10.1002/adma.201801362 · Cited by 708
Plasma exosomal α-synuclein is likely CNS-derived and increased in Parkinson’s disease
Shi, M., Liu, C., Cook, T. J., Bullock, K. M., Zhao, Y., Ginghina, C., Li, Y., Aro, P., Dator, R., He, C., et al. (2014) · Acta Neuropathologica · doi:10.1007/s00401-014-1314-y · Cited by 676
The blood-brain barrier: an engineering perspective
Wong, A. D., Ye, M., Levy, A. F., Rothstein, J. D., Bergles, D. E., & Searson, P. C. (2013) · Frontiers in Neuroengineering · doi:10.3389/fneng.2013.00007 · Cited by 662
Brain Endothelial Cell-Cell Junctions: How to “Open” the Blood Brain Barrier
Stamatovic, S. M., Keep, R. F., & Andjelkovic, A. V. (2008) · Current Neuropharmacology · doi:10.2174/157015908785777210 · Cited by 541
Emerging strategies for exploiting cannabinoid receptor agonists as medicines
Pertwee, R. G. (2009) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2008.00048.x · Cited by 436
Targeting the transferrin receptor for brain drug delivery
Johnsen, K. B., Burkhart, A., Thomsen, L. B., Andresen, T. L., & Moos, T. (2019) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2019.101665 · Cited by 379
Role of Blood-Brain Barrier in Alzheimer’s Disease
Cai, Z., Qiao, P.-F., Wan, C.-Q., Cai, M., Zhou, N.-K., & Li, Q. (2018) · Journal of Alzheimer's Disease · doi:10.3233/jad-180098 · Cited by 370
Immunologic Privilege in the Central Nervous System and the Blood–Brain Barrier
Muldoon, L. L., Alvarez, J. I., Begley, D. J., Boado, R. J., del Zoppo, G. J., Doolittle, N. D., Engelhardt, B., Hallenbeck, J. M., Lonser, R. R., Ohlfest, J. R., et al. (2012) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2012.153 · Cited by 342
IFN-γ Production by Amyloid β–Specific Th1 Cells Promotes Microglial Activation and Increases Plaque Burden in a Mouse Model of Alzheimer’s Disease
Browne, T. C., McQuillan, K., McManus, R. M., O’Reilly, J.-A., Mills, K. H. G., & Lynch, M. A. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1200947 · Cited by 330
Redox Control of Microglial Function: Molecular Mechanisms and Functional Significance
Rojo, A. I., McBean, G. J., Cindrić, M., Egea, J., López, M. G., Rada, P., Žarković, N., & Cuadrado, A. (2014) · Antioxidants and Redox Signaling · doi:10.1089/ars.2013.5745 · Cited by 323
Public health and components of particulate matter: The changing assessment of black carbon
Grahame, T. J., Klemm, R., & Schlesinger, R. B. (2014) · Journal of the Air & Waste Management Association · doi:10.1080/10962247.2014.912692 · Cited by 294
Diesel exhaust particles induce oxidative stress, proinflammatory signaling, and P‐glycoprotein up‐regulation at the blood‐brain barrier
Hartz, A. M. S., Bauer, B., Block, M. L., Hong, J., & Miller, D. S. (2008) · The FASEB Journal · doi:10.1096/fj.08-106997 · Cited by 269
Blood-Brain Barrier Disruption by Lipopolysaccharide and Sepsis-Associated Encephalopathy
Peng, X., Luo, Z., He, S., Zhang, L., & Li, Y. (2021) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2021.768108 · Cited by 284
Neurovascular Unit: a Focus on Pericytes
Sá-Pereira, I., Brites, D. M. T. O., & Brito, M. A. (2012) · Molecular Neurobiology · doi:10.1007/s12035-012-8244-2 · Cited by 280
Prevalence and impact of vascular and Alzheimer pathologies in Lewy body disease
Jellinger, K. A., & Attems, J. (2008) · Acta Neuropathologica · doi:10.1007/s00401-008-0347-5 · Cited by 267
Tight Junction in Blood‐Brain Barrier: An Overview of Structure, Regulation, and Regulator Substances
Liu, W., Wang, Z., Zhang, L., Wei, X., & Li, L. (2012) · CNS Neuroscience & Therapeutics · doi:10.1111/j.1755-5949.2012.00340.x · Cited by 258
Efficacy and Safety of A Liposome-Based Vaccine against Protein Tau, Assessed in Tau.P301L Mice That Model Tauopathy
Theunis, C., Crespo-Biel, N., Gafner, V., Pihlgren, M., López-Deber, M. P., Reis, P., Hickman, D. T., Adolfsson, O., Chuard, N., Ndao, D. M., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0072301 · Cited by 259
“Moreover, in AD and other neurological disorders, the BBB is compromised which might allow antibodies to enter the CNS more readily [47–53].”
Background
Inflammation and Adaptive Immunity in Parkinson's DiseasePreprint
Mosley, R. L., Hutter-Saunders, J. A. L., Stone, D. K., & Gendelman, H. E. (2011) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a009381 · Cited by 257
Modeling alpha-synuclein pathology in a human brain-chip to assess blood-brain barrier disruption
Pediaditakis, I., Kodella, K. R., Manatakis, D. V., Le, C. Y., Hinojosa, C., Tien-Street, W., Manolakos, E. S., Vekrellis, K., Hamilton, G. A., Ewart, L. C., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-26066-5 · Cited by 239
Blood-brain barrier alterations in ageing and dementia
Popescu, B. O., Toescu, E. C., Popescu, L. M., Bajenaru, O. A., Muresanu, D. F., Schultzberg, M., & Bogdanović, N. (2009) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2009.02.321 · Cited by 242
Neuroimmunological Processes in Parkinson’s Disease and their Relation to α-Synuclein: Microglia as the Referee between Neuronal Processes and Peripheral Immunity
Sánchez-Guajardo, V., Barnum, C. J., Tansey, M. G., & Romero‐Ramos, M. (2013) · ASN NEURO · doi:10.1042/an20120066 · Cited by 246
Therapeutic Properties and Pharmacological Activities of Asiaticoside and Madecassoside: A Review
Bandopadhyay, S., Mandal, S., Ghorai, M., Jha, N. K., Kumar, M., Radha, Ghosh, A., Proćków, J., Pérez de la Lastra, J. M., & Dey, A. (2023) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.17635 · Cited by 220
Reassessment of subacute MPTP-treated mice as animal model of Parkinson's disease
Zhang, Q.-S., Heng, Y., Mou, Z., Huang, J.-Y., Yuan, Y.-H., & Chen, N.-H. (2017) · Acta Pharmacologica Sinica · doi:10.1038/aps.2017.49 · Cited by 208
CNS tau efflux via exosomes is likely increased in Parkinson's disease but not in Alzheimer's disease
Shi, M., Kovac, A., Korff, A., Cook, T. J., Ginghina, C., Bullock, K. M., Yang, L., Stewart, T., Zheng, D., Aro, P., et al. (2016) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.04.003 · Cited by 206
Tau depletion prevents progressive blood-brain barrier damage in a mouse model of tauopathy
Blair, L. J., Frauen, H. D., Zhang, B., Nordhues, B. A., Bijan, S., Lin, Y.-C., Zamudio, F., Hernandez, L. D., Sabbagh, J. J., Selenica, M.-L. B., et al. (2015) · Acta Neuropathologica Communications · doi:10.1186/s40478-015-0186-2 · Cited by 193
Caffeine protects against MPTP‐induced blood‐brain barrier dysfunction in mouse striatum
Chen, X., Lan, X., Roche, I., Liu, R., & Geiger, J. D. (2008) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2008.05697.x · Cited by 189
Associations among Cognitive Functions, Plasma DNA, and Diffusion Tensor Image along the Perivascular Space (DTI‐ALPS) in Patients with Parkinson’s Disease
Chen, H.-L., Chen, P.-C., Lu, C.-H., Tsai, N., Yu, C.-C., Chou, K., Lai, Y., Taoka, T., & Lin, W. (2021) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2021/4034509 · Cited by 182
Regulation of BCRP (ABCG2) and P-Glycoprotein (ABCB1) by Cytokines in a Model of the Human Blood–Brain Barrier
Poller, B., Drewe, J., Krähenbühl, S., Huwyler, J., & Gutmann, H. (2009) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-009-9431-1 · Cited by 184
Tau Protein and Its Role in Blood–Brain Barrier Dysfunction
Michalicová, A., Majerová, P., & Kováč, A. (2020) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2020.570045 · Cited by 185
Role of Oxidative Stress in Blood–Brain Barrier Disruption and Neurodegenerative Diseases
Kim, S., Jung, U. J., & Kim, S. R. (2024) · Antioxidants · doi:10.3390/antiox13121462 · Cited by 189
Recent Advancements of Nanomedicine in Neurodegenerative Disorders Theranostics
Mukherjee, S., Madamsetty, V. S., Bhattacharya, D., Roy Chowdhury, S., Paul, M. K., & Mukherjee, A. (2020) · Advanced Functional Materials · doi:10.1002/adfm.202003054 · Cited by 152
Physiology of gangliosides and the role of antiganglioside antibodies in human diseases
Cutillo, G., Saariaho, A.-H., & Meri, S. (2020) · Cellular and Molecular Immunology · doi:10.1038/s41423-020-0388-9 · Cited by 154
Tau-Targeted Immunization Impedes Progression of Neurofibrillary Histopathology in Aged P301L Tau Transgenic Mice
Bi, M., Ittner, A., Ke, Y. D., Götz, J., & Ittner, L. M. (2011) · PLoS ONE · doi:10.1371/journal.pone.0026860 · Cited by 153
Blood–brain barrier alterations and their impact on Parkinson’s disease pathogenesis and therapy
Lau, K., Kotzur, R., & Richter, F. (2024) · Translational Neurodegeneration · doi:10.1186/s40035-024-00430-z · Cited by 174
Novel compound FLZ alleviates rotenone-induced PD mouse model by suppressing TLR4/MyD88/NF-κB pathway through microbiota–gut–brain axis
Zhao, Z., Li, F., Ning, J., Peng, R., Shang, J., Liu, H., Shang, M., Bao, X.-Q., & Zhang, D. (2021) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2021.03.020 · Cited by 137
Dysfunctional Cell-Cell Signaling in the Neurovascular Unit as a Paradigm for Central Nervous System Disease
Guo, S., & Lo, E. H. (2008) · Stroke · doi:10.1161/strokeaha.108.534388 · Cited by 135
Microglia in Alzheimer’s disease: A multifaceted relationship
ElAli, A., & Rivest, S. (2016) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2015.07.021 · Cited by 134
GM1 Ganglioside Is A Key Factor in Maintaining the Mammalian Neuronal Functions Avoiding Neurodegeneration
Chiricozzi, E., Lunghi, G., Biase, E. D., Fazzari, M., Sonnino, S., & Mauri, L. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21030868 · Cited by 129
Metabolomic analysis of the cerebrospinal fluid reveals changes in phospholipase expression in the CNS of SIV-infected macaques
Wikoff, W. R., Pendyala, G., Siuzdak, G. E., & Fox, H. S. (2008) · Journal of Clinical Investigation · doi:10.1172/jci34138 · Cited by 131
Neuroprotective effect of the chemical chaperone, trehalose in a chronic MPTP-induced Parkinson's disease mouse model
Sarkar, S., Chigurupati, S., Raymick, J. B., Mann, D., Bowyer, J. F., Schmitt, T., Beger, R. D., Hanig, J. P., Schmued, L. C., & Paule, M. G. (2014) · NeuroToxicology · doi:10.1016/j.neuro.2014.07.006 · Cited by 129
CB2 receptor activation prevents glial-derived neurotoxic mediator production, BBB leakage and peripheral immune cell infiltration and rescues dopamine neurons in the MPTP model of Parkinson’s disease
Chung, Y. C., Shin, W.-H., Baek, J. Y., Cho, E. J., Baik, H. H., Kim, S. R., Won, S.-Y., & Jin, B. K. (2016) · Experimental & Molecular Medicine · doi:10.1038/emm.2015.100 · Cited by 126
Revisiting the blood-brain barrier: A hard nut to crack in the transportation of drug molecules
Harilal, S., Jose, J., Parambi, D. G. T., Kumar, R., Unnikrishnan, M. K., Uddin, M. S., Mathew, G. E., Pratap, R., Marathakam, A., & Mathew, B. (2020) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2020.03.018 · Cited by 127
Role of Immunity and Inflammation in the Pathophysiology of Neurodegenerative Diseases
Fakhoury, M. (2015) · Neurodegenerative Diseases · doi:10.1159/000369933 · Cited by 124
Updates on immunity and inflammation in Parkinson disease pathology
Joshi, N., & Singh, S. (2017) · Journal of Neuroscience Research · doi:10.1002/jnr.24185 · Cited by 118
Activated Microglia Disrupt the Blood-Brain Barrier and Induce Chemokines and Cytokines in a Rat in vitro Model
Shigemoto‐Mogami, Y., Hoshikawa, K., & Sato, K. (2018) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2018.00494 · Cited by 118
Claudin‐5 regulates blood‐brain barrier permeability by modifying brain microvascular endothelial cell proliferation, migration, and adhesion to prevent lung cancer metastasis
Ma, S., Li, Q., Peng, J., Zhouwen, J., Diao, J., Niu, J., Wang, X., Guan, X., Jia, W., & Jiang, W. G. (2017) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.12764 · Cited by 117
Blood-Brain Barrier: More Contributor to Disruption of Central Nervous System Homeostasis Than Victim in Neurological Disorders
Xiao, M., Xiao, Z. J., Yang, B., Lan, Z., & Fang, F. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.00764 · Cited by 119
BBB-on-a-chip with integrated micro-TEER for permeability evaluation of multi-functionalized gold nanorods against Alzheimer’s disease
Palma-Florez, S., López-Canosa, A., Moralez-Zavala, F., Castaño, Ó., Kogan, M. J., Samitier, J., Lagunas, A., & Mir, M. (2023) · Journal of Nanobiotechnology · doi:10.1186/s12951-023-01798-2 · Cited by 116
Non‐contrast MR imaging of blood‐brain barrier permeability to water
Lin, Z., Li, Y., Su, P., Mao, D., Wei, Z., Pillai, J. J., Moghekar, A., van Osch, M. J. P., Ge, Y., & Lu, H. (2018) · Magnetic Resonance in Medicine · doi:10.1002/mrm.27141 · Cited by 106
Acteoside protects against 6-OHDA-induced dopaminergic neuron damage via Nrf2-ARE signaling pathway
Li, M., Zhou, F., Xu, T., Song, H., & Lu, B. (2018) · Food and Chemical Toxicology · doi:10.1016/j.fct.2018.06.018 · Cited by 108
The role of ABCB1 and ABCA1 in beta-amyloid clearance at the neurovascular unit in Alzheimer's disease
ElAli, A., & Rivest, S. (2013) · Frontiers in Physiology · doi:10.3389/fphys.2013.00045 · Cited by 115
T Lymphocytes and Inflammatory Mediators in the Interplay between Brain and Blood in Alzheimer’s Disease: Potential Pools of New Biomarkers
Mietelska‐Porowska, A., & Wojda, U. (2017) · Journal of Immunology Research · doi:10.1155/2017/4626540 · Cited by 111
Translation of Pre-Clinical Studies into Successful Clinical Trials for Alzheimer’s Disease: What are the Roadblocks and How Can They Be Overcome?
Banik, A., Brown, R. E., Bamburg, J., Lahiri, D. K., Khurana, D., Friedland, R. P., Chen, W., Ding, Y., Mudher, A., Padjen, A. L., et al. (2015) · Journal of Alzheimer’s Disease · doi:10.3233/jad-150136 · Cited by 102
Endothelial Dysfunction in Neurodegenerative Diseases
Fang, Y., Hsieh, Y., Hu, C., & Tu, Y. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24032909 · Cited by 102
Neurovascular abnormalities in humans and mice with Huntington's disease
Lin, C.-Y., Hsu, Y.-H., Lin, M.-H., Yang, T.-H., Chen, H.-M., Chen, Y.-C., Hsiao, H.-Y., Chen, C.-C., Chern, Y., & Chang, C. (2013) · Experimental Neurology · doi:10.1016/j.expneurol.2013.08.019 · Cited by 98
Differential receptor-mediated drug targeting to the diseased brain
Rip, J., Schenk, G., & de Boer, A. (2009) · Expert Opinion on Drug Delivery · doi:10.1517/17425240902806383 · Cited by 98
VEGF signalling causes stalls in brain capillaries and reduces cerebral blood flow in Alzheimer’s mice
Ali, M., Falkenhain, K., Njiru, B. N., Murtaza-Ali, M., Ruiz‐Uribe, N. E., Haft‐Javaherian, M., Catchers, S., Nishimura, N., Schaffer, C. B., & Bracko, O. (2021) · Brain · doi:10.1093/brain/awab387 · Cited by 118
Mortality of bullous pemphigoid in Singapore: risk factors and causes of death in 359 patients seen at the National Skin Centre
Cai, S. C. S., Allen, J. C., Lim, Y. L., Chua, S. H., Tan, S., & Tang, M. B. Y. (2013) · British Journal of Dermatology · doi:10.1111/bjd.12806 · Cited by 96
Cerebrospinal fluid proteomics implicates the granin family in Parkinson’s disease
Rotunno, M. S., Lane, M., Zhang, W., Wolf, P., Oliva, P., Viel, C., Wills, A.-M., Alcalay, R. N., Scherzer, C. R., Shihabuddin, L. S., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-59414-4 · Cited by 94
MMP-3 Contributes to Nigrostriatal Dopaminergic Neuronal Loss, BBB Damage, and Neuroinflammation in an MPTP Mouse Model of Parkinson’s Disease
Chung, Y. C., Kim, Y.-S., Bok, E., Yune, T. Y., Maeng, S., & Jin, B. K. (2013) · Mediators of Inflammation · doi:10.1155/2013/370526 · Cited by 94
Terminal complement pathway activation drives synaptic loss in Alzheimer’s disease models
Carpanini, S. M., Torvell, M., Bevan, R. J., Byrne, R. A. J., Daskoulidou, N., Saito, T., Saido, T. C., Taylor, P. R., Hughes, T. R., Zelek, W. M., et al. (2022) · Acta Neuropathologica Communications · doi:10.1186/s40478-022-01404-w · Cited by 95
The Role of Neurovascular System in Neurodegenerative Diseases
Ahmad, A., Patel, V., Xiao, J., & Khan, M. M. (2020) · Molecular Neurobiology · doi:10.1007/s12035-020-02023-z · Cited by 97
Sex differences in the blood–brain barrier and neurodegenerative diseases
Weber, C. M., & Clyne, A. M. (2021) · APL Bioengineering · doi:10.1063/5.0035610 · Cited by 95
Angiogenic activity of nicotinic acetylcholine receptors: Implications in tobacco-related vascular diseases
Egleton, R. D., Brown, K. C., & Dasgupta, P. (2008) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2008.10.007 · Cited by 91
Exercise and Neuroinflammation in Health and Disease
Seo, D.-Y., Heo, J.-W., Ko, J. R., & Kwak, H.-B. (2019) · International Neurourology Journal · doi:10.5213/inj.1938214.107 · Cited by 88
Characterization of peripheral hematopoietic stem cells and monocytes in Parkinson's disease
Funk, N., Wieghofer, P., Grimm, S., Schäfer, R., Bühring, H., Gasser, T., & Biskup, S. (2013) · Movement Disorders · doi:10.1002/mds.25300 · Cited by 81
Identifying Consensus Disease Pathways in Parkinson's Disease Using an Integrative Systems Biology Approach
Edwards, Y. J. K., Beecham, G. W., Scott, W. K., Khuri, S., Bademci, G., Tekin, D., Martin, E. R., Jiang, Z., Mash, D. C., ffrench‐Mullen, J. M. H., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0016917 · Cited by 81
Chronic cerebral hypoperfusion induces memory deficits and facilitates Aβ generation in C57BL/6J mice
Wang, L., Du, Y., Wang, K., Xu, G., Luo, S., & He, G. (2016) · Experimental Neurology · doi:10.1016/j.expneurol.2016.07.006 · Cited by 81
Mesenchymal stem cells stabilize the blood–brain barrier through regulation of astrocytes
Park, H. J., Shin, J. Y., Kim, H. N., Oh, S. H., Song, S. K., & Lee, P. H. (2015) · Stem Cell Research & Therapy · doi:10.1186/s13287-015-0180-4 · Cited by 79
Adult neurogenesis, neuroinflammation and therapeutic potential of adult neural stem cells
Taupin, P. (2008) · International Journal of Medical Sciences · doi:10.7150/ijms.5.127 · Cited by 78
Nerves and Neovessels Inhibit Each Other in the Cornea
Ferrari, G., Hajrasouliha, A. R., Sadrai, Z., Ueno, H., Chauhan, S. K., & Dana, R. (2013) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.11-8379 · Cited by 75
Functionalization strategies of polymeric nanoparticles for drug delivery in Alzheimer’s disease: Current trends and future perspectives
La Barbera, L., Mauri, E., D’Amelio, M., & Gori, M. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.939855 · Cited by 74
Mild chronic cerebral hypoperfusion induces neurovascular dysfunction, triggering peripheral beta-amyloid brain entry and aggregation
ElAli, A., Thériault, P., Préfontaine, P., & Rivest, S. (2013) · Acta Neuropathologica Communications · doi:10.1186/2051-5960-1-75 · Cited by 72
High prevalence of focal and multi-focal somatic genetic variants in the human brain
Keogh, M. J., Wei, W., Aryaman, J., Walker, L., van den Ameele, J., Coxhead, J., Wilson, I., Bashton, M., Beck, J., West, J., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-06331-w · Cited by 74
The role of mutations associated with familial neurodegenerative disorders on blood–brain barrier function in an iPSC model
Katt, M. E., Mayo, L. N., Ellis, S., Mahairaki, V., Rothstein, J. D., Cheng, L., & Searson, P. C. (2019) · Fluids and Barriers of the CNS · doi:10.1186/s12987-019-0139-4 · Cited by 69
Occludin oligomeric assembly at tight junctions of the blood-brain barrier is disrupted by peripheral inflammatory hyperalgesia
McCaffrey, G., Seelbach, M. J., Staatz, W. D., Nametz, N., Quigley, C., Campos, C. R., Brooks, T. A., & Davis, T. P. (2008) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2008.05582.x · Cited by 71
Temporal and Spatial Effects of Blast Overpressure on Blood-Brain Barrier Permeability in Traumatic Brain Injury
Kuriakose, M., Rao, K. V. R., Younger, D., & Chandra, N. (2018) · Scientific Reports · doi:10.1038/s41598-018-26813-7 · Cited by 73
Addressing Blood–Brain Barrier Impairment in Alzheimer’s Disease
Sharma, C., Woo, H., & Kim, S. R. (2022) · Biomedicines · doi:10.3390/biomedicines10040742 · Cited by 72
Improvement of Impaired Motor Functions by Human Dental Exfoliated Deciduous Teeth Stem Cell-Derived Factors in a Rat Model of Parkinson’s Disease
Chen, Y.-R., Lai, P., Chien, Y., Lee, P.-H., Lai, Y., Ma, H., Shiau, C., & Wang, K. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21113807 · Cited by 66
Mechanobiology of the blood-brain barrier during development, disease and ageing
Konig, S., Jayarajan, V., Wray, S., Kamm, R. D., & Moeendarbary, E. (2025) · Nature Communications · doi:10.1038/s41467-025-61888-7 · Cited by 72
Inhibition of Calpain Activation Protects MPTP-Induced Nigral and Spinal Cord Neurodegeneration, Reduces Inflammation, and Improves Gait Dynamics in Mice
Samantaray, S., Knaryan, V. H., Shields, D. C., Cox, A., Haque, A., & Banik, N. L. (2015) · Molecular Neurobiology · doi:10.1007/s12035-015-9255-6 · Cited by 64
Non-invasive visualization of CNS inflammation with nuclear and optical imaging
Wunder, A. P., Klohs, J., & Dirnagl, U. (2008) · Neuroscience · doi:10.1016/j.neuroscience.2008.10.005 · Cited by 65
A glycomics and proteomics study of aging and Parkinson’s disease in human brain
Raghunathan, R., Hogan, J., Labadorf, A. T., Myers, R. H., & Zaia, J. (2020) · Scientific Reports · doi:10.1038/s41598-020-69480-3 · Cited by 65
Nanotechnologies: A Strategy to Overcome Blood-Brain Barrier
Rosa, G. D., Salzano, G., Caraglia, M., & Abbruzzese, A. (2011) · Current Drug Metabolism · doi:10.2174/138920012798356943 · Cited by 62
The Protective Effect of Exercise in Neurodegenerative Diseases: The Potential Role of Extracellular Vesicles
Fuller, O. K., Whitham, M., Mathivanan, S., & Febbraio, M. A. (2020) · Cells · doi:10.3390/cells9102182 · Cited by 60
Current and emerging brain applications of MR-guided focused ultrasound
Meng, Y., Suppiah, S., Mithani, K., Solomon, B., Schwartz, M. L., & Lipsman, N. (2017) · Journal of Therapeutic Ultrasound · doi:10.1186/s40349-017-0105-z · Cited by 62
The Mechanisms of Sevoflurane-Induced Neuroinflammation
Huang, X., Ying, J., Yang, D., Fang, P., Wang, X., Zhou, B., Zhang, L., Yang, F., Yu, W., Liu, X., et al. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.717745 · Cited by 61
Adult Neurogenesis, Neural Stem Cells and Alzheimers Disease: Developments, Limitations, Problems and Promises
Taupin, P. (2009) · Current Alzheimer Research · doi:10.2174/156720509790147151 · Cited by 62
Tauroursodeoxycholic acid (TUDCA) is neuroprotective in a chronic mouse model of Parkinson’s disease
Cuevas, E., Burks, S., Raymick, J., Robinson, B., Gómez-Crisóstomo, N. P., Escudero-Lourdes, C., Lopez, A. G. G., Chigurupati, S., Hanig, J., Ferguson, S. A., et al. (2022) · Nutritional Neuroscience · doi:10.1080/1028415x.2020.1859729 · Cited by 57
Erythrocytic α-synuclein contained in microvesicles regulates astrocytic glutamate homeostasis: a new perspective on Parkinson’s disease pathogenesis
Sheng, L., Stewart, T., Yang, D., Thorland, E., Soltys, D., Aro, P., Khrisat, T., Xie, Z., Li, N., Liu, Z., et al. (2020) · Acta Neuropathologica Communications · doi:10.1186/s40478-020-00983-w · Cited by 56
Emerging Brain‐Pathophysiology‐Mimetic Platforms for Studying Neurodegenerative Diseases: Brain Organoids and Brains‐on‐a‐Chip
Bang, S., Lee, S., Choi, N., & Kim, H. N. (2021) · Advanced Healthcare Materials · doi:10.1002/adhm.202002119 · Cited by 57
Peptide-decorated nanocarriers penetrating the blood-brain barrier for imaging and therapy of brain diseases
Gao, X., Xu, J., Yao, T., Liu, X., Zhang, H., & Zhan, C. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114362 · Cited by 56
In Vitro Modeling of the Blood-Brain Barrier: Simplicity Versus Complexity
Ogunshola, O. O. (2011) · Current Pharmaceutical Design · doi:10.2174/138161211797440159 · Cited by 56
Systems biology of neurodegenerative diseases
Wood, L. B., Winslow, A. R., & Strasser, S. D. (2015) · Integrative Biology · doi:10.1039/c5ib00031a · Cited by 56
Altered neural cell junctions and ion-channels leading to disrupted neuron communication in Parkinson’s disease
Choudhury, S. P., Bano, S., Sen, S., Suchal, K., Kumar, S., Nikolajeff, F., Dey, S. K., & Sharma, V. (2022) · npj Parkinson's Disease · doi:10.1038/s41531-022-00324-9 · Cited by 52
Human iPSC‐Derived Blood‐Brain Barrier Models: Valuable Tools for Preclinical Drug Discovery and Development?
Appelt‐Menzel, A., Oerter, S., Mathew, S., Haferkamp, U., Hartmann, C., Jung, M., Neuhaus, W., & Pleß, O. (2020) · Current Protocols in Stem Cell Biology · doi:10.1002/cpsc.122 · Cited by 56

Authors: Desai, B. S., Monahan, A. J., Carvey, P. M., & Hendey, B.
Affiliations: Department of Pharmacology, Rush University Medical Center, Chicago IL, USA
Rush University Medical Center (US)
Venue: Cell Transplantation
Publisher: SAGE Publications
Published: 2007-03
Volume: 16
Issue: 3
Pages: 285-299
ISSN: 0963-6897 (ISSN-L)
1555-3892
DOI: 10.3727/000000007783464731
OpenAlex: W2316522881
Cited by: 339
References: 117
Citations by year: 2026: 13 · 2025: 14 · 2024: 28 · 2023: 31 · 2022: 23 · 2021: 33 · 2020: 37 · 2019: 13 · 2018: 15 · 2017: 16 · 2016: 11 · 2015: 12 · 2014: 12 · 2013: 18 · 2012: 8
FWCI: 1.29
Type: journal article
Language: en
Open access: green
doaj.org
Licence: cc-by-sa
journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
Locations: Cell Transplantation (publishedVersion)
PubMed (publishedVersion)
DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders: National Institutes of Health (5r01ns045316-03, W81XWH-04-01-0365)
U.S. Public Health Service (012307)
National Institute of Allergy and Infectious Diseases (R01AI051619, R01AI51619)
National Institute of Neurological Disorders and Stroke (NS045316)
Topics: Life Sciences › Neuroscience › Neurology › Barrier Structure and Function Studies
Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
Keywords: blood-brain barrier, Alzheimer's disease, Parkinson's disease, BBB dysfunction, tight junctions, blood-brain barrier permeability, neuroinflammation, neurodegeneration, brain drug delivery, vessel density, neurodegenerative disease therapeutics
MeSH terms: Alzheimer Disease, Biological Transport, Blood-Brain Barrier, Humans, Parkinson Disease, Disease Progression

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Blood–Brain Barrier Pathology in Alzheimer's and Parkinson's Disease: Implications for Drug Therapy

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks